IL98562A - ) + (R-2-] 4-] Tetrahydro-2-furanil [carbonyl [- 1-piperazinyl] -6,7-dimethoxy-4-quinazolinamine and pharmaceutical preparations containing it - Google Patents

) + (R-2-] 4-] Tetrahydro-2-furanil [carbonyl [- 1-piperazinyl] -6,7-dimethoxy-4-quinazolinamine and pharmaceutical preparations containing it

Info

Publication number
IL98562A
IL98562A IL9856291A IL9856291A IL98562A IL 98562 A IL98562 A IL 98562A IL 9856291 A IL9856291 A IL 9856291A IL 9856291 A IL9856291 A IL 9856291A IL 98562 A IL98562 A IL 98562A
Authority
IL
Israel
Prior art keywords
tetrahydro
quinazolinamine
furanyl
compound
piperazinyl
Prior art date
Application number
IL9856291A
Other languages
English (en)
Hebrew (he)
Original Assignee
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Lab filed Critical Abbott Lab
Publication of IL98562A publication Critical patent/IL98562A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
IL9856291A 1990-06-29 1991-06-19 ) + (R-2-] 4-] Tetrahydro-2-furanil [carbonyl [- 1-piperazinyl] -6,7-dimethoxy-4-quinazolinamine and pharmaceutical preparations containing it IL98562A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/546,349 US5212176A (en) 1990-06-29 1990-06-29 R(+)-terazosin
CA002086974A CA2086974C (en) 1990-06-29 1993-01-08 R(+)-terazosin

Publications (1)

Publication Number Publication Date
IL98562A true IL98562A (en) 1995-12-31

Family

ID=25675811

Family Applications (1)

Application Number Title Priority Date Filing Date
IL9856291A IL98562A (en) 1990-06-29 1991-06-19 ) + (R-2-] 4-] Tetrahydro-2-furanil [carbonyl [- 1-piperazinyl] -6,7-dimethoxy-4-quinazolinamine and pharmaceutical preparations containing it

Country Status (14)

Country Link
US (1) US5212176A (ja)
EP (1) EP0536329B1 (ja)
JP (1) JPH07119222B2 (ja)
AT (1) ATE136779T1 (ja)
AU (1) AU654148B2 (ja)
CA (1) CA2086974C (ja)
DE (1) DE69118889T2 (ja)
DK (1) DK0536329T3 (ja)
ES (1) ES2089224T3 (ja)
GR (1) GR3020364T3 (ja)
IE (1) IE72967B1 (ja)
IL (1) IL98562A (ja)
PT (1) PT98148B (ja)
WO (1) WO1992000073A1 (ja)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL101243A (en) * 1991-03-20 1999-12-22 Merck & Co Inc Pharmaceutical preparations for the treatment of benign prostatic hyperplasia containing steroid history
JPH08502977A (ja) * 1992-11-04 1996-04-02 セプラコア，インコーポレイテッド 良性前立腺増殖およびアテローム性動脈硬化の治療法ならびに（＋）ドキサゾシン組成物
EP0667776A1 (en) * 1992-11-04 1995-08-23 Sepracor, Inc. Methods and compositions of (+) doxazosin for the treatment of hypertension
US5294615A (en) * 1993-04-29 1994-03-15 Abbott Laboratories Terazosin polymorph and pharmaceutical composition
US5412095A (en) * 1993-04-29 1995-05-02 Abbott Laboratories Terazosin monohydrochloride and processes and intermediate for its production
US5504207A (en) * 1994-10-18 1996-04-02 Abbott Laboratories Process and intermediate for the preparation of terazosin hydrochloride dihydrate
US5587377A (en) * 1995-10-24 1996-12-24 Invamed, Inc. Terazosin crystalline polymorph and pharmaceutical compositions thereof
WO1997017967A1 (en) * 1995-11-15 1997-05-22 Merck & Co., Inc. ALPHA 1a ADRENERGIC RECEPTOR ANTAGONISTS
DE19546573A1 (de) * 1995-12-13 1997-06-19 Uetikon Chemie Gmbh Kristallines Polymorph von Terazosin-Hydrochlorid, sowie Verfahren zu seiner Herstellung
US5952003A (en) * 1996-08-01 1999-09-14 Novartis Corporation Terazosin capsules
US5922722A (en) * 1996-11-12 1999-07-13 Merck & Co., Inc. Alpha 1a adrenergic receptor antagonists
IT1286789B1 (it) * 1996-11-29 1998-07-17 Alfa Chem Ital Processo per la produzione della forma i del terazosin monocloridato anidro
GB9708917D0 (en) * 1997-05-01 1997-06-25 Pfizer Ltd Compounds useful in therapy
US6376503B1 (en) 1997-06-18 2002-04-23 Merck & Co., Inc Alpha 1a adrenergic receptor antagonists
US6080760A (en) * 1997-06-18 2000-06-27 Merck & Co., Inc. Alpha 1A adrenergic receptor antagonists
US6037354A (en) * 1997-06-18 2000-03-14 Merck & Co., Inc. Alpha 1a adrenergic receptor antagonists
US6214832B1 (en) 1997-06-18 2001-04-10 Merck & Co., Inc. Bis-piperidinyl-pyrimidin-2-ones as alpha 1a adrenergic receptor antagonists
US6143750A (en) * 1997-06-18 2000-11-07 Merck & Co., Inc. Alpha 1a adrenergic receptor antagonists
US6057350A (en) * 1997-06-18 2000-05-02 Merck & Co., Inc. Alpha 1a adrenergic receptor antagonists
US6248888B1 (en) 1997-11-14 2001-06-19 Teva Pharmaceutical Industries Ltd. Process for the preparation of terazosin hydrochloride dihydrate
WO2000006565A1 (en) 1998-07-30 2000-02-10 Merck & Co., Inc. ALPHA 1a ADRENERGIC RECEPTOR ANTAGONISTS
AU1808400A (en) 1998-10-29 2000-05-22 Merck & Co., Inc. Dihydropyridinones and pyrrolinones useful as alpha 1a adrenoceptor antagonists
US6319932B1 (en) 1998-11-10 2001-11-20 Merck & Co., Inc. Oxazolidinones useful as alpha 1A adrenoceptor antagonists
US6228870B1 (en) 1998-11-10 2001-05-08 Merck & Co., Inc. Oxazolidinones useful as alpha 1a adrenoceptor antagonists
WO2000029386A1 (en) 1998-11-12 2000-05-25 Merck & Co., Inc. Pyrimidinedione derivatives useful as alpha 1a adrenoceptor antagonists
DE19856440C2 (de) * 1998-12-08 2002-04-04 Bosch Gmbh Robert Übertragungsrahmen und Funkeinheit mit Übertragungsrahmen
DE19856441C5 (de) * 1998-12-08 2004-11-18 Robert Bosch Gmbh Verfahren zur Übertragung von Kurznachrichten
US6358959B1 (en) 1999-01-26 2002-03-19 Merck & Co., Inc. Polyazanaphthalenone derivatives useful as alpha 1a adrenoceptor antagonists
GB2355457A (en) 1999-09-30 2001-04-25 Merck & Co Inc Novel spirotricyclic substituted azacycloalkane derivatives useful as alpha 1a adrenoceptor antagonists
GB2355264A (en) 1999-09-30 2001-04-18 Merck & Co Inc Spirohydantoin derivatives useful as alpha 1a adrenoceptor antagonists
GB2355263A (en) 1999-09-30 2001-04-18 Merck & Co Inc Lactam and cyclic urea derivatives useful as alpha 1a adrenoceptor antagonists
GB2355456A (en) 1999-09-30 2001-04-25 Merck & Co Inc Novel arylhydantoin derivatives useful as alpha 1a adrenoceptor antagonists
US6200573B1 (en) 1999-12-03 2001-03-13 Starcor Pharmaceuticals, Inc. Method of medical management for lower urinary tract symptoms and benign prostatic hyperplasia
US6313172B1 (en) 2000-04-13 2001-11-06 Allergan Sales, Inc. Methods and compositions for modulating alpha adrenergic receptor activity
US7335803B2 (en) 2001-10-19 2008-02-26 Allergan, Inc. Methods and compositions for modulating alpha adrenergic receptor activity
JP2002121188A (ja) * 2000-07-18 2002-04-23 Toray Ind Inc ピペラジンアミド化合物の製造法およびピペラジンテトラヒドロフラン−２−カルボン酸アミド誘導体
US20020198215A1 (en) * 2000-10-23 2002-12-26 Lino Tavares Terazosin transdermal device and methods
US6534542B2 (en) 2001-02-27 2003-03-18 Allergen Sales, Inc. (2-hydroxy)ethyl-thioureas useful as modulators of α2B adrenergic receptors
EP2266590A3 (en) 2002-02-22 2011-04-20 Shire LLC Active agent delivery sytems and methods for protecting and administering active agents
US7091232B2 (en) 2002-05-21 2006-08-15 Allergan, Inc. 4-(substituted cycloalkylmethyl) imidazole-2-thiones, 4-(substituted cycloalkenylmethyl) imidazole-2-thiones, 4-(substituted cycloalkylmethyl) imidazol-2-ones and 4-(substituted cycloalkenylmethyl) imidazol-2-ones and related compounds
US7358269B2 (en) 2002-05-21 2008-04-15 Allergan, Inc. 2-((2-Thioxo-2,3-dihydro-1H-imidazol-4-yl)methyl)-3,4-dihydronapthalen-1(2H)-one
US7323485B2 (en) 2002-05-21 2008-01-29 Allergan, Inc. 4-(substituted cycloalkylmethyl) imidazole-2-thiones, 4-(substituted cycloalkenylmethyl) imidazole-2-thiones, 4-(substituted cycloalkylmethyl) imidazol-2-ones and 4-(substituted cycloalkenylmethyl) imidazol-2-ones and related compounds
US7276522B2 (en) 2002-05-21 2007-10-02 Allergan, Inc. 4-(substituted cycloalkylmethyl) imidazole-2-thiones, 4-(substituted cycloalkenylmethyl) imidazole-2-thiones, 4-(substituted cycloalkylmethyl) imidazol-2-ones, 4-(substituted cycloalkenylmethyl) imidazol-2-ones and related compounds
KR20060126448A (ko) 2003-09-12 2006-12-07 알러간, 인코포레이티드 통증 및 다른 알파 2 아드레날린 매개 증상을 치료하기위한 방법 및 조성물
US7390829B2 (en) 2005-06-29 2008-06-24 Allergan, Inc. Alpha-2 adrenergic agonists
US7323477B2 (en) 2006-02-02 2008-01-29 Allergan, Inc. 7-((1H-imidazol-4-yl)methyl)-5,6,7,8-tetrahydroquinoline
WO2008021891A2 (en) * 2006-08-08 2008-02-21 Auspex Pharmaceuticals, Inc. Preparation and utility of substituted quinazoline compounds with alpha-adrenergic blocking effects
US7598417B2 (en) 2007-04-12 2009-10-06 Allergan, Inc. Substituted fluoroethyl ureas as alpha 2 adrenergic agents
WO2008147788A1 (en) 2007-05-23 2008-12-04 Allergan, Inc. Therapeutic ((phenyl)imidazolyl)methylquinolinyl compounds
ES2395875T3 (es) 2007-05-23 2013-02-15 Allergan, Inc. Lactamas cíclicas para el tratamiento del glaucoma o de la presión intraocular elevada
US7829587B2 (en) 2008-01-09 2010-11-09 Allergan, Inc. Substituted 2-aminotetralin derivatives as selective alpha 2B agonist
US7902247B2 (en) 2008-01-09 2011-03-08 Allergan, Inc. Substituted-aryl-2-phenylethyl-1H-imidazole compounds as subtype selective modulators of alpha 2B and/or alpha 2C adrenergic receptors
US8362022B2 (en) 2008-01-18 2013-01-29 Allergan, Inc. Selective subtype alpha 2 adrenergic agents and methods for use thereof
US8809379B2 (en) 2008-01-18 2014-08-19 Allergan, Inc. Selective subtype alpha 2 adrenergic agents and methods for use thereof
US20090239918A1 (en) * 2008-03-24 2009-09-24 Allergan, Inc. Selective subtype alpha 2 adrenergic agents and methods for use thereof
US9072727B2 (en) 2008-04-18 2015-07-07 Warsaw Orthopedic, Inc. Alpha adrenergic receptor agonists for treatment of degenerative disc disease
US8420114B2 (en) 2008-04-18 2013-04-16 Warsaw Orthopedic, Inc. Alpha and beta adrenergic receptor agonists for treatment of pain and / or inflammation
EP2280707A1 (en) 2008-05-05 2011-02-09 Allergan, Inc. Alpha2b and alpha2c agonists
JP5710470B2 (ja) 2008-05-16 2015-04-30 アラーガン インコーポレイテッドＡｌｌｅｒｇａｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ 選択的サブタイプアルファ２アドレナリン作用薬及びこれらの使用方法
JP5705742B2 (ja) 2008-12-08 2015-04-22 アラーガン インコーポレイテッドＡｌｌｅｒｇａｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ アルファ２ｂまたはアルファ２ｂおよびアルファ２ｃアドレノセプターのサブタイプ選択性モジュレーターとしてのｎ‐（１‐フェニル‐２‐アリールエチル）‐４，５‐ジヒドロ‐３ｈ‐ピロール‐２‐アミン化合物
AU2010210513A1 (en) 2009-02-06 2011-09-01 Allergan, Inc. Pyridine compounds as subtype selective modulators of alpha2B and/or alpha 2C adrenergic receptors
EP2459542B1 (en) 2009-07-30 2014-10-29 Allergan, Inc. Substituted N-benzyl-4,5-dihydrooxazol-2-amines useful as selective alpha 2B/2C receptor agonists
EP2486009B1 (en) 2009-10-06 2019-08-21 Allergan, Inc. 2h-pyrrol-5-amine derivatives as alpha adrenergic receptor modulators
US20160361380A1 (en) 2015-06-12 2016-12-15 Nymox Corporation Combination compositions for treating disorders requiring removal or destruction of unwanted cellular proliferations
US11224572B1 (en) * 2020-08-17 2022-01-18 Novitium Pharma LLC Stable oral liquid composition of terazosin

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4026894A (en) * 1975-10-14 1977-05-31 Abbott Laboratories Antihypertensive agents
GB1591490A (en) * 1977-08-04 1981-06-24 Abbott Lab 1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-(2-tetrahydrofuroyl)piperazine hydrochloride dihydrate
JPH01216983A (ja) * 1988-02-26 1989-08-30 Hiroyuki Nohira （±）−テトラヒドロフラン−２−カルボン酸の光学分割方法

Also Published As

Publication number Publication date
PT98148A (pt) 1993-08-31
CA2086974C (en) 2001-04-10
AU654148B2 (en) 1994-10-27
GR3020364T3 (en) 1996-09-30
ES2089224T3 (es) 1996-10-01
DE69118889D1 (en) 1996-05-23
EP0536329B1 (en) 1996-04-17
EP0536329A1 (en) 1993-04-14
IE72967B1 (en) 1997-05-07
WO1992000073A1 (en) 1992-01-09
DE69118889T2 (de) 1996-11-07
US5212176A (en) 1993-05-18
EP0536329A4 (en) 1993-05-19
DK0536329T3 (da) 1996-08-12
JPH05507280A (ja) 1993-10-21
ATE136779T1 (de) 1996-05-15
AU8323191A (en) 1992-01-23
PT98148B (pt) 1998-12-31
IE912086A1 (en) 1992-01-01
JPH07119222B2 (ja) 1995-12-20
CA2086974A1 (en) 1994-07-09

Similar Documents

Publication Publication Date Title
CA2086974C (en) R(+)-terazosin
CA2698384C (en) 3-pyridyl enantiomers and their use as analgesics
EP1273575B1 (en) Diazepane derivatives or salts thereof
JP2003534377A (ja) メラノコルチン受容体作働薬
SK8032000A3 (en) (benzodioxan, benzofuran or benzopyran) derivatives having fundic relaxation properties
JPH11503127A (ja) 新規なヘテロ環式化合物
KR20040107520A (ko) (에스)-4-아미노-5-클로로-2-메톡시-엔-[1-[1-(2-테트라히드로푸릴카르보닐)-4-피페리디닐메틸]-4-피페리디닐]벤즈아미드, 그것의 제조방법, 그것을 함유하는 약제학적 조성물,및 그것을 위한 중간체
AU700304B2 (en) Use of alpha-1C specific compounds to treat benign prostatic hyperplasia
JPH0469377A (ja) ジフェニルメチルピペラジン誘導体
US7795281B2 (en) Optically active dihydropyridine derivative
US5221675A (en) Aza-spirocyclic compounds that enhance cholinergic neurotransmission
CZ224098A3 (cs) Derivát chinolin-2-(1H)-onu, způsob jeho přípravy a farmaceutický prostředek, který ho obsahuje
CN100348583C (zh) 四氢异喹啉衍生物的对映异构体及其药用盐,它们的制剂及药物组合物
CZ114299A3 (cs) N-Substituované azaheterocyklické sloučeniny
Moser et al. Structure-activity relationships of new analogues of arecaidine propargyl ester at muscarinic M1 and M2 receptor subtypes.
US4882337A (en) Tetrahydroisoquinoline antiarrhythmic agents
CN109096251B (zh) 具有组胺受体双重拮抗活性的化合物及用途
US20030022900A1 (en) Compositions comprising alpha-1C specific compounds
EP0851865A1 (en) Novel heterocyclic compounds
FI114705B (fi) Kinolonijohdannainen virtsainkontinenssin hoitoon
US6696574B2 (en) Processes and intermediates for preparing glycogen phosphorylase inhibitors
AU710265B2 (en) 3(2h)-pyridazinone derivatives and pharmaceutical compositions containing these compounds
JP2577184B2 (ja) セコアポルフィン誘導体及びその製造方法、並びに不整脈治療剤
KR0132014B1 (ko) 신규의 치환된 이미다졸 유도체 및 그의 제조방법
JPS59193884A (ja) １，４−ジヒドロピリジン誘導体

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees